Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Non-Current Liabilities (2019 - 2021)

Pliant Therapeutics (PLRX) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $22.2 million as the latest value for Q4 2021.

  • On a quarterly basis, Total Non-Current Liabilities rose 91.02% to $22.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was $22.2 million, a 91.02% increase, with the full-year FY2021 number at $22.2 million, up 91.02% from a year prior.
  • Total Non-Current Liabilities was $22.2 million for Q4 2021 at Pliant Therapeutics, up from $12.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $22.2 million in Q4 2021 to a low of $9.1 million in Q4 2019.
  • A 3-year average of $12.7 million and a median of $11.8 million in 2020 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 91.02% in 2021; the steepest drop was 13.12% in 2021.
  • Pliant Therapeutics' Total Non-Current Liabilities stood at $9.1 million in 2019, then rose by 27.83% to $11.6 million in 2020, then surged by 91.02% to $22.2 million in 2021.
  • Per Business Quant, the three most recent readings for PLRX's Total Non-Current Liabilities are $22.2 million (Q4 2021), $12.9 million (Q3 2021), and $10.9 million (Q2 2021).